Chronic exposure of glucose rich environment creates several physiological and
pathophysiological changes. There are several pathways by which hyperglycemia …

Metformin is the most commonly prescribed drug for type 2 diabetes mellitus. In recent years,
in addition to glucose lowering, several studies have presented evidence suggesting some …

When energy supply is low, organisms respond by slowing aging and increasing resistance
to diverse age-related pathologies. Targeting the mechanisms underpinning this response …

Discovering the biological basis of aging is one of the greatest remaining challenges for
science. Work on the biology of aging has discovered a range of interventions and pathways …

The association between hyperglycemia and inflammation and vascular complications in
diabetes is now well established. Antidiabetes drugs may alleviate inflammation by reducing …

Laboratory research and pharmacoepidemiology are providing converging evidence that
the widely used antidiabetic drug metformin has antineoplastic activity, but there are …

As the prevalence of diabetes mellitus is substantially increasing worldwide, associated
diseases such as renal failure, cardiovascular diseases, fatty liver, and cancers have also …

Type 2 diabetes mellitus is a recognized risk factor for HCC in patients with liver disease,
independent from the etiology of their liver disease. Hence, prevention and treatment of type …

Diabetes mellitus (DM), one of the most common life-threatening illnesses worldwide, is a
group of metabolic diseases, characterized by sustained hyperglycemia. The global …

Hepatocellular carcinoma (HCC) mortality rates are increasing globally, and particularly in
the Western world. Cirrhosis remains the predominant risk factor for HCC. However …